Johnson Fistel Continues Investigation on Behalf of DexCom, Inc. Shareholders

Core Viewpoint - Johnson Fistel, PLLP has initiated an investigation into DexCom, Inc. for potential breaches of fiduciary duties and violations of federal securities laws due to misleading public statements made by certain insiders regarding the company's expansion strategy and market share [1][2]. Summary by Relevant Sections Investigation Details - The investigation focuses on actions taken by DexCom insiders between April 28, 2023, and June 5, 2024, which led to the issuance of false and misleading statements about the company's growth and market position [2]. - DexCom began making corrective disclosures starting April 25, 2024, revealing that its growth and business prospects were significantly lower than previously claimed [2]. - By the final corrective disclosure on July 25, 2024, DexCom's share price had decreased by over 40.6% [2]. Shareholder Rights - Current stockholders who held DexCom stock before April 28, 2023, are encouraged to contact Johnson Fistel to discuss their legal rights regarding the investigation [3].